We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
ImmunoMet is a clinical stage biotech utilizing cellular metabolism to develop novel anti-tumor and immuno-metabolism therapies. ImmunoMet was founded in 2015 as a is Spin-off from HanAll Biopharma, a mid-sized Korean pharma co, and is headquartered at Houston JLABs near MD Anderson. We have raised $20 M post spin-off including $10 M from VCs. Our lead molecule, IM156, is an OXPHOS inhibitor which has demonstrated impressive in vivo efficacy in resistant solid tumors and entered Phase 1 in 4Q17. ImmunoMet owns a large biguanide library which forms an engine we are leveraging to unlock value and develop products in immuno-metabolism.